## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Analyst consensus $262 (+12% upside). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($224.88)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Iqvia stock hits 52-week high at 234.33 USD By Investing.com**
- Source: Investing.com UK | 20260105T203626 | Bullish | Relevance: 100%
- Iqvia Holdings Inc. (IQV) stock reached a 52-week high of $234.33, reflecting a 14.17% return over the past year and a 37.22% surge in six months, with a "GOOD" financial health rating and a market cap of $39.87 billion. Despite trading near its peak, InvestingPro's Fair Value analysis suggests the stock is slightly undervalued, with analysts setting targets as high as $273. Recent strategic moves include refinancing loans, a partnership with Amazon Web Services for AI-powered clinical trial automation, and the appointment of Nobel laureate Dr. William G. Kaelin Jr. to its board.

**2. Iqvia stock hits 52-week high at 234.33 USD By Investing.com**
- Source: Investing.com Canada | 20260105T211956 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. (IQV) stock has reached a new 52-week high of $234.33, driven by strong market performance, with a 14.17% return over the past year and a 37.22% surge in six months. The company, which has a market cap of $39.87 billion and a "GOOD" financial health rating, is seen as slightly undervalued according to InvestingPro's Fair Value analysis. Recent strategic moves, such as refinancing existing loans and a collaboration with Amazon Web Services, along with positive analyst price target revisions, suggest continued investor confidence and growth prospects for the life sciences tools and services provider.

**3. JARISLOWSKY FRASER Ltd Sells 7,365 Shares of IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20260103T143158 | Somewhat-Bullish | Relevance: 100%
- JARISLOWSKY FRASER Ltd reduced its holdings in IQVIA Holdings Inc. by 0.9% in Q3, selling 7,365 shares and retaining 785,658 shares valued at $149.2 million. Insider Eric Sherbet also sold 4,000 shares for approximately $878,800. IQVIA exceeded quarterly earnings and revenue expectations and has a consensus "Moderate Buy" rating with an average target price near $243.

**4. IQVIA Holdings Inc. $IQV Shares Sold by Generali Asset Management SPA SGR**
- Source: MarketBeat | 20260103T114706 | Bullish | Relevance: 100%
- Generali Asset Management SPA SGR reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 15.5% in Q3 2025, selling 5,827 shares and retaining 31,797 shares valued at approximately $6.04 million. Despite this sale, multiple brokers, including UBS, JPMorgan, and Baird, have raised their price targets and ratings for IQVIA, resulting in a consensus "Moderate Buy" rating and a target price of $243.19. The company also surpassed Q3 estimates with $3.00 EPS and $4.10 billion revenue and provided optimistic FY2025 EPS guidance.

**5. North Growth Management Ltd. Increases Stock Holdings in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20260104T130827 | Somewhat-Bullish | Relevance: 95%
- North Growth Management Ltd. significantly increased its stake in IQVIA Holdings Inc. by 33.3% in Q3, now holding 44,000 shares valued at over $8.3 million. This comes as institutional investors own nearly 90% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average target price of $243.19, following IQVIA's better-than-expected Q3 EPS.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $4.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +3.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 18.1x stretched relative to 9% growth. Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.0B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.95 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 18.1 |
| Current P/E | 19.7 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.9% to 4.3% (+3.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 2.7% confirms short-term momentum alignment. AM_20 at 4.5% shows strong absolute momentum above own 20MA. Outperforming sector by 3.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.33% (CS: 84) | Strong |
| RSI_14 | 67.2 | Neutral |
| MACD Histogram | 0.44 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.275x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $234.62
- **Stop Loss:** $224.88 (4.2% risk)
- **Target:** $254.10 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $20,646.56
- **Portfolio %:** 20.65%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*